These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31106957)

  • 1. Estimation of Nuwiq
    Tiefenbacher S; Albisetti M; Baker P; Kappert G; Kitchen S; Kremer Hovinga JA; Pouplard C; Scholz U; Ternisien C; Borgvall C; Vicente T; Belyanskaya L; Walter O; Oldenburg J;
    Haemophilia; 2019 Jul; 25(4):708-717. PubMed ID: 31106957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.
    Kitchen S; Beckmann H; Katterle Y; Bruns S; Tseneklidou-Stoeter D; Maas Enriquez M
    Haemophilia; 2016 May; 22(3):e192-9. PubMed ID: 27030173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
    Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
    Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
    Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
    Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Nuwiq
    Zozulya N; Kessler CM; Klukowska A; von Depka M; Hampton K; Hay CRM; Jansen M; Bichler J; Knaub S; Rangarajan S
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
    Augustsson C; Norström E; Lind V; Martin M; Astermark J; Strandberg K
    Haemophilia; 2021 May; 27(3):494-500. PubMed ID: 33866649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
    Tiefenbacher S; Clausen WHO; Hansen M; Lützhøft R; Ezban M
    Haemophilia; 2019 Sep; 25(5):893-901. PubMed ID: 31294905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers.
    Ketteler C; Hoffmann I; Davidson S; Tiede A; Richter N
    Haemophilia; 2021 Nov; 27(6):e704-e712. PubMed ID: 34590394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.
    Sommer JM; Moore N; McGuffie-Valentine B; Bardan S; Buyue Y; Kamphaus GD; Konkle BA; Pierce GF
    Haemophilia; 2014 Mar; 20(2):294-300. PubMed ID: 24261554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical variation in factor VIII one-stage and chromogenic assays: Experiences from the ECAT external quality assessment programme.
    van Moort I; Meijer P; Priem-Visser D; van Gammeren AJ; Péquériaux NCV; Leebeek FWG; Cnossen MH; de Maat MPM
    Haemophilia; 2019 Jan; 25(1):162-169. PubMed ID: 30488994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog-alfa).
    Guy S; Bowyer AE; Shepherd MF; Maclean RM; Kitchen S
    Int J Lab Hematol; 2024 Feb; 46(1):135-140. PubMed ID: 37799011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability, immunogenicity and efficacy of Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Bichler J; Jansen M; Dzhunova I; Liesner RJ
    Haemophilia; 2018 Jul; 24(4):595-603. PubMed ID: 29582516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
    Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International comparative field study of N8 evaluating factor VIII assay performance.
    Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
    Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.
    Lissitchkov T; Klukowska A; Pasi J; Kessler CM; Klamroth R; Liesner RJ; Belyanskaya L; Walter O; Knaub S; Bichler J; Jansen M; Oldenburg J
    Ther Adv Hematol; 2019; 10():2040620719858471. PubMed ID: 31263528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.
    St Ledger K; Feussner A; Kalina U; Horn C; Metzner HJ; Bensen-Kennedy D; Blackman N; Veldman A; Stowers A; Friedman KD
    J Thromb Haemost; 2018 Mar; 16(3):555-564. PubMed ID: 29274194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
    Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.
    Winge S; Yderland L; Kannicht C; Hermans P; Adema S; Schmidt T; Gilljam G; Linhult M; Tiemeyer M; Belyanskaya L; Walter O
    Protein Expr Purif; 2015 Nov; 115():165-75. PubMed ID: 26318235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay.
    Pouplard C; Caron C; Aillaud MF; Ternisien C; Desconclois C; Dubanchet A; Sobas F
    Haemophilia; 2011 Sep; 17(5):e958-62. PubMed ID: 21457408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study.
    Church N; Leong L; Katterle Y; Ulbrich HF; Noerenberg I; Kitchen S; Michaels LA
    Haemophilia; 2018 Sep; 24(5):823-832. PubMed ID: 29984531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.